Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
MediumReport
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at Morgan Stanley from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
LowReport
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at Morgan Stanley from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $19.00 to $21.00. They now have a "buy" rating on the stock.
LowReport
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $19.00 to $21.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: